ECM
IONS icon

Everence Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Everence Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$468K Sell
6,232
-538
-8% -$42.5K 0.03% 398
2025
Q4 		$536K Hold
6,770
– – 0.03% 372
2025
Q3 		$443K Hold
6,770
– – 0.03% 433
2025
Q2 		$267K Hold
6,770
– – 0.02% 628
2025
Q1 		$204K Hold
6,770
– – 0.01% 737
2024
Q4 		$237K Buy
+6,770
New +$253K 0.02% 696

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Everence Capital Management's IONS Position: Q1 2026 in Review

Everence Capital Management reduced its Ionis Pharmaceuticals (IONS) stake by 7.9% in Q1 2026, selling an estimated $42.5K and leaving 6,232 shares worth $468K. The position accounts for 0.03% of the portfolio, ranked #398.

Everence Capital Management first reported a position in IONS in Q4 2024 and has held it in 6 quarters since. The position peaked at $536K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Everence Capital Management held 6,232 shares of Ionis Pharmaceuticals worth $468K as of Q1 2026.
  • Everence Capital Management sold 538 Ionis Pharmaceuticals shares in Q1 2026, an estimated $42.5K.
  • Ionis Pharmaceuticals made up 0.03% of Everence Capital Management's portfolio in Q1 2026, its #398 holding.
  • Everence Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Everence Capital Management's Ionis Pharmaceuticals position peaked at $536K in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.